Topics · healthcare
MarkdownHSA Post-marketing Vigilance Guidance 2026
HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.
Record details
- Description
- HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.
- Also known as
- HSA post-marketing vigilance, therapeutic product adverse-event reporting Singapore, CTGTP vigilance guidance
- Evidence profile
- mixed
- Part of
- Healthcare
Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force.
Collection as of 2026-11-22 · An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.
Machine-readable: JSON · sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026